Literature DB >> 12062486

Evidence for de novo sphingolipid biosynthesis in Toxoplasma gondii.

Nahid Azzouz1, Beatrice Rauscher, Peter Gerold, Marie-France Cesbron-Delauw, Jean-François Dubremetz, Ralph T Schwarz.   

Abstract

Glycolipids are important components of cellular membranes involved in various biological functions. In this report, we describe the identification of the de novo synthesis of glycosphingolipids by Toxoplasma gondii tachyzoites. Parasite-specific glycolipids were identified by metabolic labelling of parasites with tritiated serine and galactose. These glycolipids were characterised as sphingolipids based on the labelling protocol and their insensitivity towards alkaline treatment. Synthesis of parasite glycosphingolipids were inhibited by threo-phenyl-2-palmitoylamino-3-morpholino-1-propanol and L-cycloserine, two well-established inhibitors of de novo sphingolipid biosynthesis. The identified glycolipids were insensitive towards treatment with endoglycoceramidase II indicating that they might belong to globo-type glycosphingolipids. Taken together, we provide evidence for the first time that T. gondii is capable of synthesising glycosphingolipids de novo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062486     DOI: 10.1016/s0020-7519(02)00009-7

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  15 in total

Review 1.  Sphingolipids in parasitic protozoa.

Authors:  Kai Zhang; James D Bangs; Stephen M Beverley
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  Neospora caninum Recruits Host Cell Structures to Its Parasitophorous Vacuole and Salvages Lipids from Organelles.

Authors:  Sabrina J Nolan; Julia D Romano; Thomas Luechtefeld; Isabelle Coppens
Journal:  Eukaryot Cell       Date:  2015-03-06

3.  CRISPR/Cas9 and glycomics tools for Toxoplasma glycobiology.

Authors:  Elisabet Gas-Pascual; Hiroshi Travis Ichikawa; Mohammed Osman Sheikh; Mariam Isabella Serji; Bowen Deng; Msano Mandalasi; Giulia Bandini; John Samuelson; Lance Wells; Christopher M West
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

Review 4.  Host Organelle Hijackers: a similar modus operandi for Toxoplasma gondii and Chlamydia trachomatis: co-infection model as a tool to investigate pathogenesis.

Authors:  Julia D Romano; Isabelle Coppens
Journal:  Pathog Dis       Date:  2013-07-22       Impact factor: 3.166

Review 5.  Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans.

Authors:  Srinivasan Ramakrishnan; Mauro Serricchio; Boris Striepen; Peter Bütikofer
Journal:  Prog Lipid Res       Date:  2013-07-01       Impact factor: 16.195

6.  Inhibitory effect of aureobasidin A on Toxoplasma gondii.

Authors:  Sabrina Sonda; Giusy Sala; Riccardo Ghidoni; Andrew Hemphill; Jean Pieters
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Fierce competition between Toxoplasma and Chlamydia for host cell structures in dually infected cells.

Authors:  Julia D Romano; Catherine de Beaumont; Jose A Carrasco; Karen Ehrenman; Patrik M Bavoil; Isabelle Coppens
Journal:  Eukaryot Cell       Date:  2012-12-14

Review 8.  Targeting lipid biosynthesis and salvage in apicomplexan parasites for improved chemotherapies.

Authors:  Isabelle Coppens
Journal:  Nat Rev Microbiol       Date:  2013-10-28       Impact factor: 60.633

9.  Introduction of caveolae structural proteins into the protozoan Toxoplasma results in the formation of heterologous caveolae but not caveolar endocytosis.

Authors:  Bao Lige; Julia D Romano; Vera Sampels; Sabrina Sonda; Keith A Joiner; Isabelle Coppens
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  Toxoplasma gondii salvages sphingolipids from the host Golgi through the rerouting of selected Rab vesicles to the parasitophorous vacuole.

Authors:  Julia D Romano; Sabrina Sonda; Emily Bergbower; Maria Elisa Smith; Isabelle Coppens
Journal:  Mol Biol Cell       Date:  2013-04-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.